貝達藥業(300558.SZ)子公司Xcovery被BETA起訴 涉及服務商標權侵犯糾紛
格隆匯2月16日丨貝達藥業(300558.SZ)公佈，公司控股子公司Xcovery Holdings, Inc.(“Xcovery”)近日收到了美國佛羅里達南區聯邦法院送達的傳票和《起訴狀》，原告Beta Pharma Inc.(“BETA”)訴稱被告Xcovery使用其公司標語“Better Medicine Better Life”侵犯了原告的商標權。
原告BETA訴稱其在商業活動中使用“Better Medicine Better Life”標語已有十餘年。最近，BETA發現Xcovery將該“Better Medicine Better Life”標語用在科學會議、行業展會以及Xcovery的網站上，可能造成公眾混淆、誤認，侵犯原告BETA的“Better Medicine Better Life”這一服務商標權。
根據《起訴狀》，BETA的主要訴訟請求包括：
1、裁定、發佈初步和永久禁令，禁止Xcovery在藥物研發服務方面或以可能導致對服務提供者、贊助關係以及和Xcovery提供服務事項造成困惑、誤認的任何其它形式使用“Better Medicine Better Life”；
2、判令被告賠償原告補償性損失，包括但不限於(i)BETA丟失的利潤；(ii)Xcovery非法所得(利潤和收入)；(iii)BETA名譽減損、丟失客户、丟失客户關係、丟失收入、商譽損失以及其它所導致的損失；
3、判令被告賠償原告因被告故意侵權導致的實際損失至三倍；
4、判令被告賠償原告懲罰性損失；
5、判令被告賠償原告利息、成本、律師費、專家費；
6、判令原告獲衡平法救濟，以頒佈禁令、強行使用法定信託、會計和沒收非法所得等形式；
7、裁定、發佈訴前財產保全，扣押Xcovery 資產；
8、其它法院認為合適的救濟措施。
“Better Medicine Better Life”是公司創辦時提出的創意和表述，表達了創業團隊開發創新藥物的使命和方向。該標語自提出以來一直伴隨公司成長，作為公司使命的英文表述被廣泛用於公司宣傳冊、學術推廣海報、網站等宣傳媒介中，至今已被公眾熟知和識別。且早在2013年6月貝達藥業推進企業上市之際，公司與BETA就涉及的商號、商標、企業標誌等知識產權簽署協議，明確權利歸屬和使用範圍。鑑於對企業宣傳用語表述的統一管理，公司安排控股子公司Xcovery在網頁、國際展會上使用“Better Medicine Better Life”。
經公司核查，BETA於2020年1月3日向美國專利和商標局提交了“Better Medicine Better Life”作為服務商標的申請，目前處於待審狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
